Rachel Blank

Rachel Blank is the Founder and CEO of Allara, a pioneering virtual care platform dedicated to addressing the unique healthcare needs of women, particularly those living with complex chronic conditions such as polycystic ovary syndrome (PCOS). Under her leadership, Allara has developed a comprehensive care model that integrates lifestyle, nutrition, exercise, and medical expertise to provide personalized treatment plans for women experiencing hormonal, metabolic, and gynecologic issues.135

Background and Education

Rachel Blank holds a Bachelor of Science degree from the University of Virginia, where she graduated with distinction from the McIntire School of Commerce, focusing on finance and accounting. She furthered her education by earning an MBA from Harvard Business School.25

Professional Experience

Before founding Allara in August 2020, Rachel served as the Director of Strategy at Ro, a healthcare technology company, where she was also a co-founder of Rory, a women's health brand under Ro. Her previous roles include positions at General Catalyst and Echo360, Inc., where she honed her skills in corporate development and strategic analysis.23

Vision for Women's Health

Rachel's motivation to create Allara stemmed from her own experiences as a patient diagnosed with PCOS. She recognized significant gaps in women's healthcare and aimed to build a system that provides compassionate and specialized care, ensuring women feel seen and heard throughout their healthcare journeys.35 Since its inception, Allara has rapidly expanded its services and community engagement, recently closing a $10 million Series A funding round to further enhance its offerings across multiple states.34

Impact and Community Engagement

Allara has successfully built a community of over 100,000 followers and has seen substantial growth in its patient base. The platform emphasizes direct engagement with patients to tailor services to their specific needs, addressing not only PCOS but also other gynecologic and metabolic conditions like endometriosis and hypothyroidism.34 Rachel's commitment to improving women's health continues to resonate within the industry, as evidenced by the increasing support from investors and health tech stakeholders.35